Key result
Racial, ethnic, and socioeconomic factors linked to inequities in novel P2Y12 inhibitor initiation and adherence post-PCI.
Why the study?
The association of racial, ethnic, and socioeconomic factors with initiation of and adherence to novel P2Y12 inhibitors after ACS was not well characterized.
Are racial, ethnic, and socioeconomic factors associated with the initiation of and adherence to novel P2Y12 inhibitors in a commercially insured population after PCI?
Are racial, ethnic, and socioeconomic factors associated with the initiation of and adherence to novel P2Y12 inhibitors in a commercially insured population after PCI?
Disparities in novel P2Y12 initiation and adherence by ethnicity and income persist among insured ACS patients; leaves open targeted equity interventions.
Novel P2Y12 inhibitors prasugrel and ticagrelor were approved for patients with acute coronary syndrome (ACS) in 2009 and 2011, respectively. We assessed the association of racial, ethnic, and socioeconomic factors with initiation of and adherence to novel P2Y12 inhibitors in a commercially insured population.
No takes yet. Share an insight, caveat, or question.
Nathan et al. (2022) studied this question. Racial, ethnic, and socioeconomic factors are associated with inequities in the initiation of and adherence to novel P2Y12 inhibitors after percutaneous coronary intervention.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: